RETROSPECTIVE ANALYSIS OF OUTCOME DIFFERENCES IN PREOPERATIVE CONCURRENT CHEMORADIATION WITH OR WITHOUT ELECTIVE NODAL IRRADIATION FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA

被引:56
作者
Hsu, Feng-Ming [1 ,3 ,5 ]
Lee, Jang-Ming [2 ]
Huang, Pei-Ming [2 ]
Lin, Chia-Chi [1 ,3 ]
Hsu, Chih-Hung [1 ,3 ]
Tsai, Yu-Chieh [1 ,3 ]
Lee, Yung-Chie [2 ]
Cheng, Jason Chia-Hsien [1 ,3 ,4 ,5 ]
机构
[1] Natl Taiwan Univ, Coll Med, Natl Taiwan Univ Hosp, Dept Oncol, Taipei 100, Taiwan
[2] Natl Taiwan Univ, Coll Med, Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan
[3] Natl Taiwan Univ, Coll Med, Canc Res Ctr, Taipei 100, Taiwan
[4] Natl Taiwan Univ, Coll Med, Grad Inst Oncol, Taipei 100, Taiwan
[5] Natl Taiwan Univ, Grad Inst Biomed Elect & Bioinformat, Taipei 100, Taiwan
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2011年 / 81卷 / 04期
关键词
Esophageal cancer; Squamous cell carcinoma; Preoperative chemo-radiation; Elective nodal irradiation; PHASE-III TRIAL; DEFINITIVE CHEMORADIOTHERAPY; RADIATION-THERAPY; RANDOMIZED-TRIAL; RADIOTHERAPY; CANCER; SURGERY; CHEMOTHERAPY;
D O I
10.1016/j.ijrobp.2011.04.032
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Purpose: To evaluate the efficacy and patterns of failure of elective nodal irradiation (ENI) in patients with esophageal squamous cell carcinoma (SCC) undergoing preoperative concurrent chemoradiation (CCRT) followed by radical surgery. Methods and Materials: We retrospectively studied 118 patients with AJCC Stage II to III esophageal SCC undergoing preoperative CCRT (median, 36 Gy), followed by radical esophagectomy. Of them, 73 patients (62%) had ENI and 45 patients (38%) had no ENI. Patients with ENI received radiotherapy to either supraclavicular (n = 54) or celiac (n = 19) lymphatics. Fifty-six patients (57%) received chemotherapy with paclitaxel plus cisplatin. The 3-year progression-free survival, overall survival, and patterns of failure were analyzed. Distant nodal recurrence was classified into M1a and M1b regions. A separate analysis using matched cases was conducted. Results: The median follow-up was 38 months. There were no differences in pathological complete response rate (p = 0.12), perioperative mortality rate (p = 0.48), or delayed Grade 3 or greater cardiopulmonary toxicities (p = 0.44), between the groups. More patients in the non-ENI group had M1a failure than in the ENI group, with 3-year rates of 11% and 3%, respectively (p = 0.05). However, the 3-year isolated distant nodal (M1a + M1b) failure rates were not different (ENI, 10%; non-ENI, 14%; p = 0.29). In multivariate analysis, pathological nodal status was the only independent prognostic factor associated with overall survival (hazard ratio = 1.78, p = 0.045). The 3-year overall survival and progression-free survival were 45% and 45%, respectively, in the ENI group, and 52% and 43%, respectively, in the non-ENI group (p = 0.31 and 0.89, respectively). Matched cases analysis did not show a statistical difference in outcomes between the groups. Conclusions: ENI reduced the M1a failure rate but was not associated with improved outcomes in patients undergoing preoperative CCRT for esophageal SCC. Pathological nodal metastasis predicted poor outcome. (C) 2011 Elsevier Inc.
引用
收藏
页码:E593 / E599
页数:7
相关论文
共 16 条
[1]
Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial [J].
Burmeister, BH ;
Smithers, BM ;
Gebski, V ;
Fitzgerald, L ;
Simes, RJ ;
Devitt, P ;
Ackland, S ;
Gotley, DC ;
Joseph, D ;
Millar, J ;
North, J ;
Walpole, ET ;
Denham, JW .
LANCET ONCOLOGY, 2005, 6 (09) :659-668
[2]
STUDY TO DETERMINE ADEQUATE MARGINS IN RADIOTHERAPY PLANNING FOR ESOPHAGEAL CARCINOMA BY DETAILING PATTERNS OF RECURRENCE AFTER DEFINITIVE CHEMORADIOTHERAPY [J].
Button, Michael R. ;
Morgan, Carys A. ;
Croydon, Elizabeth S. ;
Roberts, S. Ashley ;
Crosby, Thomas D. L. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 73 (03) :818-823
[3]
The pattern and prevalence of lymphatic spread in thoracic oesophageal squamous cell carcinoma [J].
Chen, Junqiang ;
Liu, Suoyan ;
Pan, Jianji ;
Zheng, Xiongwei ;
Zhu, Kunshou ;
Zhu, Ji ;
Xiao, Jinrong ;
Ying, Mingang .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2009, 36 (03) :480-486
[4]
Chemoradiotherapy of locally advanced esophageal cancer - Long-term follow-up of a prospective randomized trial (RTOG 85-01) [J].
Cooper, JS ;
Guo, MD ;
Herskovic, A ;
Macdonald, JS ;
Martenson, JA ;
Al-Sarraf, M ;
Byhardt, R ;
Russell, AH ;
Beitler, JJ ;
Spencer, S ;
Asbell, SO ;
Graham, MV ;
Leichman, LL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (17) :1623-1627
[5]
czito Brian G, 2008, PEREZ BRADYS PRINCIP, P1131
[6]
Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis [J].
Gebski, Val ;
Burmeister, Bryan ;
Smithers, B. Mark ;
Foo, Kerwyn ;
Zalcberg, John ;
Simes, John .
LANCET ONCOLOGY, 2007, 8 (03) :226-234
[7]
Ho DE., 2007, J STAT SOFTW
[8]
Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus [J].
Ishikura, S ;
Nihei, K ;
Ohtsu, A ;
Boku, N ;
Hironaka, S ;
Mera, K ;
Muto, M ;
Ogino, TG ;
Yoshida, S .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (14) :2697-2702
[9]
Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer [J].
Kleinberg, L ;
Knisely, JPS ;
Heitmiller, R ;
Zahurak, M ;
Salem, R ;
Burtness, B ;
Heath, EI ;
Forastiere, AA .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 56 (02) :328-334
[10]
A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma [J].
Lee, JL ;
Park, SI ;
Kim, SB ;
Jung, HY ;
Lee, GH ;
Kim, JH ;
Song, HY ;
Cho, KJ ;
Kim, WK ;
Lee, JS ;
Kim, SH ;
Min, YI .
ANNALS OF ONCOLOGY, 2004, 15 (06) :947-954